Reprogramming Stem Cells to Attack Cancer Cells

The immune system has particularly specialized cells called invariant natural killer T cells (iNKT) . Although very rare in the body, they are more powerful than other immune cells. In September 2019, Cell Stem Cell published a study in which a method enabling invariant natural killer T cells to attack cancer cells more effectively was discovered. When these cells were used in mouse models with different cancers, tumor growth was suppressed.
Invariant natural killer T cells (iNKT) are promising for cancer treatment because they target multiple cancer cells simultaneously. However, humans have very few of these cells. They account for less than 0.1% of all blood cells. Some previous clinical studies found longer survival in patients with higher iNKT levels.
An advantage of this approach is that it is a one-time cell treatment that may provide patients with iNKT cells for life.
Researchers aimed to develop a permanent treatment enabling the body to produce more iNKT cells. They first used hematopoietic stem cells , normally found in bone marrow and capable of developing into all blood and immune cells. By modifying stem cells through genetic engineering, researchers successfully converted them into iNKT cells.
Invariant natural killer T cells obtained through hematopoietic stem cell engineering were transplanted into mouse cells carrying human cancer cells (myeloma and melanoma). Increased iNKT cell numbers and cessation of tumor growth were observed in mice.
What Does This Study Mean for Us?
- Further research is needed to determine whether stem cell-derived iNKT cells benefit human cancer treatment and to understand their long-term side effects.
- The most exciting aspect is that a single treatment sends very large numbers of iNKT cells to fight cancer and may remain active for a long time.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.